Asbestos, a known occupational pollutant, may upregulate the activity of inducible nitric oxide synthase (iNOS) and thus the production of nitric oxide(NO). This study investigated whether iNOS (CCTTT)(n) polymorphism is associated with an increased asbestosis risk in exposed workers. The study cohort consisted of 262 cases with asbestosis and 265 controls with no asbestos-related disease. For each subject the cumulative asbestos exposure data were available. The number of CCTTT repeats was determined following PCR amplification of the iNOS promoter region. Logistic regression was performed to estimate asbestosis risk. The OR of asbestosis was 1.20 (95% CI = 0.85-1.69) for the LL genotype compared to the combined SL and SS genotypes and 1.26 (95% CI = 0.86-1.85) for the LL genotype compared to the SL genotype.The results of this study are borderline significant and suggest a possible role of iNOS (CCTTT)(n) polymorphism in the risk of asbestosis; however, further studies are needed.
COBISS.SI-ID: 29376473
Platinum-based therapy is widely used in the treatment of malignant mesothelioma (MM); however, the efficacy and toxicity of platinum agents vary greatly between patients. In total, 133 patients with MM were genotyped for common XPD, ERCC1, and GSTP1 polymorphisms, as well as for GSTM1 and GSTT1 gene deletion. We observed associations of XPD and ERCC polymorphisms and haplotypes with survival and the occurrence of adverse effects in patients with MM who received platinum agents. GST polymorphisms were not associated with treatment outcome in these patients.
COBISS.SI-ID: 28755417
The goal of the personalized medicine is the prevention and early detection and adequate treatment of the diseases. Treatment efficacy and safety can improve by tailoring the treatment according to the patient's genetic characteristics. The currect potentials and the existing hurdels for the introduction of pharmacogenetic testing into clinical practice were presented in the invited lecture.
COBISS.SI-ID: 29617113